Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new, extensive systematic review has identified significant research gaps in the treatment of scrub typhus which could be improved by developing a database for individual participant data (IPD) to enable more detailed analyses to address important knowledge gaps such as the optimum dosing for children and to improve patient outcomes.

Women sitting in front of huts, traditional village in Southeast Asia © Pearl Gan

Scrub typhus is an acute febrile illness caused by intracellular bacteria from the genus Orientia. It is estimated that one billion people are at risk, with one million cases annually mainly affecting rural areas in Asia-Oceania. Scrub typhus is difficult to diagnose clinically without laboratory tests because it lacks reliable distinguishing features that differentiate it from other febrile illnesses prevalent in the endemic areas, such as typhoid fever, dengue fever and malaria. This difficulty in diagnosis is one of the main reasons for the current limited epidemiological knowledge on scrub typhus.

With scant and scattered data, it is difficult to identify the most at-risk populations, the regional distribution, and the optimal treatments to support disease control efforts. National treatment recommendations for scrub typhus vary or are simply not stated, and the absence of WHO recommendations illustrates the lack of high-quality supportive evidence for optimal treatments.

Researchers concluded there is substantial value in developing an IPD platform that will facilitate pooling and harmonisation of currently scattered data and enable in-depth investigation of priority research questions that can ultimately inform clinical practice and improve health outcomes for scrub typhus patients. The authors have called for scrub typhus to be recognised as a neglected tropical disease (NTD) by the WHO and the research community, which will help to increase awareness of the disease.

“The heterogeneous nature of the available data reflects the absence of consensus in treatment and research methodologies and poses a significant barrier to aggregating information across available published data without access to the underlying individual participant-level data (IPD). There is likely to be a substantial amount of data available to address knowledge gaps.” First author Kartika Saraswati

Read the publication 'Systematic review of the scrub typhus treatment landscape: Assessing the feasibility of an individual participant-level data (IPD) platform' on the PLOS Neglected Tropical Diseases website

The full story is available on the IDDO website

Similar stories

RECOVERY Trial wins ‘Oscar of Higher Education’ for STEM Research Project of the year

The RECOVERY Trial has been awarded the 2021 Times Higher Education (THE) Award in the ‘Research Project of the Year: STEM’ category.

Antibiotic accountability: how countries and companies perform

Patients in north Africa and the Middle East are using antibiotics in sharply rising quantities far beyond the global average, raising concerns over the escalating risks of resistance to medicines to treat bacterial infections. Estimated antibiotic consumption for 204 countries between 2000 and 2018 shows a 46 per cent increase in global antibiotic usage, with a surge in nations including India and Vietnam.

Paul Newton named ASTMH Distinguished International Fellow

Professor Paul Newton was announced new Distinguished International Fellow at the ASTMH Annual Meeting Awards Ceremony on the 17th November. This distinction formally recognizes individuals who have made eminent contributions to a particular aspect of tropical medicine or hygiene.

The global burden of Plasmodium vivax malaria is obscure and insidious

Until recently, Plasmodium falciparum dominated the malaria research landscape, and Plasmodium vivax infection was considered benign and inconsequential. We now know that this is not true: if not properly diagnosed and treated, P. vivax can lead to life-threatening syndromes and death. Professor Kevin Baird from EOCRU in Jakarta, Indonesia talks to OutBreak News Today

GRAM study provides the first longitudinal estimates of global antibiotic consumption in 204 countries from 2000 to 2018

Global antibiotic consumption rates increased by 46 percent in the last two decades, according to the first study to provide longitudinal estimates for human antibiotic consumption covering 204 countries from 2000 to 2018, published in Lancet Planetary Health by the Global Research on Antimicrobial Resistance (GRAM) Project.

COVID-19 research at OUCRU

Despite unprecedented disruptions caused globally by SARS-Cov-2, OUCRU has responded remarkably and addressed almost every important aspect of the pandemic, from its societal impact to viral genomic surveillance and COVID-19 therapy